KalVista Pharmaceuticals, Inc. (KALV) announced on Monday the appointment of Jeb Ledell as its new Chief Operating Officer. Bringing over two decades of leadership and operational expertise in the biotechnology sector, Ledell transitions from AVEO Oncology, now part of LG Chem, where he executed similar responsibilities managing AVEO’s operational strategy.
Before his tenure at AVEO, Ledell served as COO at Enzyvant Therapeutics and has held significant leadership roles at Compass Therapeutics and Horizon Discovery Group. This strategic appointment comes as KalVista gears up for the global launch of sebetralstat.
Ben Palleiko, Chief Executive Officer of KalVista, expressed confidence in Ledell’s capabilities, stating, "I am confident that his proven skills will help us achieve our goal of delivering sebetralstat to help transform the lives of people living with hereditary angioedema."
In pre-market trading on the Nasdaq, KalVista’s shares saw a slight decline of approximately 1.6%, bringing the stock down to $8.55.
